Capital Flow Monitor · Sponsors · CIK 1708696
Instylla, Inc.
201 BURLINGTON ROAD, BEDFORD, MA, 01730 · 617-510-3859
Biotechnology · Corporation· inc. DELAWARE true
Fit score
—
Offering
$35.0M
Sold
$34.8M
% sold
99.3%
Investors
29
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-07-28 | D/A ·current | 506(b) | $35.0M | $34.8M | 99.3% | 29 | EDGAR ↗ |
| 2025-10-23 | D | 506(b) | $21.7M | $21.7M | 100.0% | 25 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Daniel Davis — Director, BEDFORD, MA
- Sean Boyle — Director, BEDFORD, MA
-
Amarpreet Sawhney — Executive Officer, BEDFORD, MA
1 other raise
- StataDx, Inc. $1.9M of $2.5M · 75.9%
-
Henry Chen — Director, BEDFORD, MA
1 other raise
- Averna Therapeutics Inc. $85.0M of $85.0M · 100.0%
- Tasneem Dohadwala — Director, BEDFORD, MA
- Farhad Khosravi — Director, BEDFORD, MA
-
Darshana Zaveri — Director, BEDFORD, MA
1 other raise
- Aria CV, Inc. $1.4M of $6.0M · 23.0%
- Steven Cagnetta — Executive Officer, BEDFORD, MA
-
Sean Cheng — Director, BEDFORD, MA
1 other raise
- CSA Medical, Inc. $2.9M of $11.2M · 25.9%
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.